Background. Although cyclosporine maintenance therapy reduces the risk of acute rejection and increases short-term graft survival in renal transplant recipients, its associated nephrotoxicity increases the risk of chronic graft dysfunction. The dose that allows an optimal risk-to-benefit ratio has not been established.
Introduction
In recent years, various minimization strategies have been proposed to reduce maintenance immunosuppressive drug exposure in renal transplant recipients with the goal of limiting the risk of both nephrotoxicity and cardiovascular side effects. Minimization strategies have focused on calcineurin inhibitor (CNI)-sparing regimens such as avoidance, withdrawal, dose reduction or dose replacement [1] [2] [3] . While withdrawal has resulted in an increased risk of acute rejection [4] [5] [6] , CNI dose-reduction studies have demonstrated improvements in renal function without an excess risk of acute rejection [7] [8] [9] . Yet, the optimal balance of the dose at which nephrotoxicity is avoided while concurrently preserving low rates of acute rejection remains to be defined. While immunological monitoring could assist in defining and maintaining this balance, unfortunately, in its absence, the only currently viable approach is pharmacokinetic monitoring.
The aim of the DIminution of Cyclosporine in Association with Mycophenolate Mofetil (DICAM) Study was to assess the benefit of reducing cyclosporine exposure by 50% during the second post-transplant year in a homogeneous sample of deceased-donor renal allograft recipients who were no longer receiving corticosteroids.
Materials and methods
This prospective, randomized study was conducted at seven transplantation centres in France (ClinicalTrials.gov number, NCT00213590). The study was approved by the coordinating centre's ethics committee, the Committee for the Protection of Persons Engaged in Biomedical Research of Haute Normandie and conducted in accordance with the Helsinki Declaration. Written informed consent was obtained from all patients before enrolment.
Study population
Eligible patients were 18-75 years of age and primary or secondary renal transplant recipients in their second year post-transplant with stable serum creatinine levels (i.e. <20% variation for the previous 3 months). All patients must have received induction therapy, been corticosteroid-free for at least 3 months and receiving combination maintenance therapy consisting of cyclosporine (trough level, 125-175 ng/ml) and mycophenolate mofetil (CellCept, F. Hoffmann-La Roche AG, Basel, Switzerland) 2 g daily. A majority of the participating centres maintained patients at a low immunological risk on cyclosporine alone [10, 11] and those at high risk of graft dysfunction were usually maintained on corticosteroids. Thus, patients at either low or high risk of graft dysfunction were ineligible for inclusion in the study. Low-risk patients were those who had zero or one acute rejection episode with a return of renal function to previous levels after corticosteroid treatment, panel-reactive antibody titre <25%, serum creatinine level <125 μmol/L, age >25 years and donor age <40 years. High-risk patients had at least one of the following: a serum creatinine level >250 μmol/L, proteinuria >1 g/day, panel-reactive antibody titre >80%, >1 episode of T cell-mediated rejection or at least one episode of antibody-mediated rejection post-transplant or the presence of vasculitis or systemic lupus erythematosus that usually were treated with corticosteroids.
Other exclusion criteria were evidence of systemic infection or malignancy within the previous 5 years (except adequately treated nonmetastatic basal or squamous cell carcinoma of the skin), leukocyte count <2.5x10 3 /μl, haemoglobin <80 g/dl, platelet count <100 × 10 3 /μl, severe intestinal disorders, pregnancy, breastfeeding or current immunosuppressive treatment with drugs other than cyclosporine and mycophenolate mofetil. Women of childbearing age were required to use adequate contraception during treatment with mycophenolate mofetil and for 6 weeks after its discontinuation.
Randomization and treatment
Patients were randomized 1:1 at each centre to receive cyclosporine microemulsion (Neoral, Novartis, Basel, Switzerland) either at a usualexposure or a low-exposure level. The randomization code was generated and maintained by the Biostatistics Department at the University of Rouen. Randomization was performed independently at each centre using sealed envelopes. The usual-exposure level was based on the mean area under the concentration-time curve (AUC 0-12 h ) measured at 1 year post-transplant in 93 patients from the participating centres between 1999 and 2000. In the usual-exposure group, the cyclosporine AUC 0-12 h target was 4.3 mg h/L (range, 3.5-4.8 mg h/L) and, in the low-exposure group, the target was 50% of the usual cyclosporine AUC 0-12 h target or 2.2 mg h/L (range, 2.0-2.6 mg h/L). Ranges were asymmetrical for safety reasons (i.e. to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm). The AUC 0-12 h [12] was estimated using a Bayesian estimator [13] and a three-point limited sampling strategy (0, 1 and 3 h), adjusting for the assay method (enzyme-multiplied immunoassay, fluorescence polarization immunoassay). Although yet unpublished, this estimator had been validated in several independent groups of patients, the most recent comprising 18 stable renal transplant patients enrolled in another CNI-sparing trial [14] in which we were involved.
A computer programme was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC 0-12 h was determined every 2 months.
Mycophenolic acid exposure (AUC 0-12 h ) was estimated at Months 0, 6, 12 and 24 using an ad hoc pharmacokinetic model [15] , a Bayesian estimator [16] and three plasma samples (20 min and 1 and 3 h post-dose). A central laboratory froze the samples until analysed by liquid chromatography-tandem mass spectrometry. Mycophenolic acid concentrations and AUC 0-12 h measurements were not revealed to the clinicians during the trial (a calculator for determining cyclosporine and mycophenolic acid AUC 0-12 h is available at https://pharmaco.chu-limoges.fr/abis.htm).
Study endpoints
The primary endpoint was the proportion of patients with treatment failure (failure to prevent kidney dysfunction) at 24 months, which was a composite of three mutually exclusive outcomes (only the first event was counted for each patient), namely, graft loss, histologically confirmed acute rejection or cyclosporine toxicity or a >15% increase in the mean serum creatinine level from the baseline assessment. The level at baseline and the level at 2 years were calculated as the means of the current and two previous serum creatinine levels; for the baseline level, means at Months 1 and 2 prior to inclusion and the level at inclusion were used, while means at Months 20, 22 and 24 were used to calculate the level at 2 years. The mean of the current and two previous serum creatinine levels was also used to determine the level at the nadir (the time of the lowest serum creatinine level).
The secondary endpoints included the change in estimated glomerular filtration rate (eGFR) from baseline, calculated using the four-variable equation from the Modification of Diet in Renal Disease (MDRD) Study [17] ; blood pressure, urinary protein and lipid levels; severe adverse events such as infection requiring hospitalization, neoplasia or lymphoma; and graft and patient survival.
Study follow-up and procedures
Weight, blood pressure after a 10-min rest, serum creatinine and glucose levels, a complete blood cell count and urinary protein levels were measured, and the use of immunosuppressive, antihypertensive and lipidlowering drugs was recorded at baseline and every 2 months. Serum lipid levels were measured at baseline and every 6 months. Gynaecologic and dermatologic examinations were performed at baseline and yearly. Adverse events were recorded. If the serum creatinine levels increased from the prior visit, it was recommended that the investigator identify possible causes such as dehydration, a vascular or urologic source or drug-drug interactions.
Renal biopsies were performed when creatinine levels increased >20% relative to the nadir or when proteinuria was >1 g/day. The nadir level was used as a reference point to obviate the risk of missing or delaying the diagnosis of rejection in the low-exposure arm; serum creatinine levels usually fell after the initiation of a low-exposure regimen. Biopsies were classified using the Banff 1997 criteria [18] initially by a local experienced pathologist then a second central review was completed by four expert pathologists. The pathologists were blinded to the treatment group/clinical status during the retrospective review of the biopsies. CNI-associated nephrotoxicity was graded mild, moderate or severe according to the Banff 1997 chronicity rejection scores [18] .
Statistical analyses
To detect a 15% absolute difference in treatment failure (18 versus 33%), the primary endpoint, with 80% power and a two-sided 0.05 significance level, 208 evaluable patients (104 in each group) were needed for enrolment. Treatment outcomes were analysed for the intention-to-treat population that included those patients who received allocation intervention. Fig. 1 . Patient distribution. The asterisk indicates the other exclusion criteria which included systemic infection; malignancy; severe intestinal disorder; low leukocyte, erythrocyte or platelet count; inadequate contraception; and declined participation.
For the calculation of treatment failure, patients who had more than one outcome were counted as one failure.
The treatment groups were compared using Pearson's chi-square test or Fisher's exact test as appropriate for dichotomous outcomes and using Student's t-test for continuous outcomes, and the Mann-Whitney test was used where distributions were non-Gaussian. Adjusted comparisons for the primary endpoint relied on logistic regression with two steps: one in which adjustment was for baseline covariates only and one for which mean mycophenolic acid AUC 0-12 h over follow-up was additionally adjusted. Continuous variables were expressed as the mean ± standard deviation (SD). Non-biased estimation of inter-subject and intra-subject variability in trough levels and AUC in both treatment groups was obtained using Type II (random effect), repeated-measures analysis of variance. Coefficients of variations were derived from the variance values found for the 'patients' and 'visits (within-patients)' factors [19] . A post hoc linear regression analysis of the relationship between mean eGFR and follow-up time points (Months 2 through 24) was stratified by exposure group and included only patients who remained on their allocated treatment. Jacques Bénichou, professor of biostatistics, and Pierre Marquet, professor of pharmacology, conducted the data analyses using the SAS software version 8.02 (SAS Institute, Inc., Cary, NC) and Excel 2002 SP3 (Microsoft, Redmond, WA).
Results

Baseline characteristics
Between April 2000 and June 2004, 212 patients were randomized (n = 104 in the cyclosporine usual-exposure group and n = 108 in the low-exposure group; Figure 1 ). Four patients were excluded secondarily, leaving 208 pa- tients in the intention-to-treat population. One patient in the usual-exposure group died of drowning during follow-up. Hence, the intention-to-treat sample available for analysis consisted of 207 patients, 101 in the usual-exposure and 106 in the low-exposure groups. The two groups had similar baseline characteristics, except for the higher rate of cytomegalovirus infection and its treatment and the longer time from transplantation to enrolment in the low-exposure group (Table 1 ) [17] . More than 94% of patients in each group had primary transplants. 
Immunosuppressive drug exposure
At every bimonthly post-baseline assessment, mean cyclosporine AUC 0-12 h , trough concentrations and dose were significantly lower in the cyclosporine low-exposure group than in the usual-exposure group (P < 0.001) (Figure 2A and B) . In addition, the non-biased estimates of intra-patient and inter-patient coefficients of variation of bimonthly post-baseline cyclosporine AUC were lower than those of the bimonthly trough concentration in the low-exposure group: 16.4 versus 30.6 and 27.2 versus 56.5%, respectively. At 24 months, the mean cyclosporine AUC 0-12 h was 4.2 ± 0.8 and 2.4 ± 0.5 mg h/L in the usual-exposure and low-exposure groups, respectively (P < 0.001), representing a 43% reduction (Table 2 ). In the low-exposure group, the coefficient of variation of the cyclosporine AUC was lower than that of the trough concentration, respectively, 0.21 and 0.30.
Mycophenolic acid AUC 0-12 h increased significantly at 6 months (47.2 ± 16.3 mg h/L), 12 months (46.8 ± 16.5 mg h/L) and 24 months (48.3 ± 18.6 mg h/L) relative to baseline (42.7 ± 14.1 mg h/L) in the low-exposure group (P = 0.004, 0.02 and 0.006, respectively), but in the usual-exposure group, the increase in mycophenolic acid AUC 0-12 h was not significant. At 24 months, the mean mycophenolic acid AUC 0-12 h was 42.4 ± 15.6 and 48.3 ± 18.6 mg h/L in the usual-exposure and low-exposure groups, respectively (P = 0.03), representing a 14% increase.
Efficacy outcomes
The proportion of patients experiencing treatment failure was about 2-fold higher in the cyclosporine usual-exposure group (37 out of 101, 37%) than in the low-exposure group (19 out of 106, 18%) (P = 0.003; Table 2 ). An explanation of the occurrences of each component of treatment failure follows and their relationship is illustrated (Figure 3 ). Only one graft loss occurred in the cyclosporine usual-exposure group due to thrombotic microangiopathy. In the usualexposure group, three episodes of biopsy-proven acute rejection occurred, all during the second year of followup, whereas in the low-exposure group, six episodes of biopsy-proven acute rejection occurred (P = 0.50), five during the first 6 months of follow-up. Corticosteroid treatment of acute rejection was discontinued in one out of three (33%) patients in the usual-exposure group and in three out of six (50%) patients in the low-exposure group. The median eGFR reductions at 2 years among patients with episodes of acute rejection were 30 and 38%, respectively; no patient required dialysis. Patients who experienced an acute rejection episode had lower minimum mycophenolic acid AUC 0-12 h than patients who did not (27.8 versus The serum creatinine value of patients from the time of dialysis was arbitrarily reported as 884 μmol/L.
37.0 mg h/L, respectively; P = 0.03). Nephrotoxicity occurred in 12 out of 101 (12%) patients in the usualexposure group and in five out of 106 (5%) patients in the low-exposure group (P = 0.08). Graft loss, acute rejection episodes or nephrotoxicity episodes occurred in 16 out of 101 (16%) patients in the usual-exposure group and in 11 out of 106 (10%) patients in the low-exposure group (P = 0.24). An increase in serum creatinine level >15% at 2 years occurred in 26 out of 101 (26%) patients in the usual-exposure group and in 16 out of 106 (15%) patients in the low-exposure group (P = 0.06).
In a multivariate logistic regression analysis, treatment failure was more frequent in the usual-exposure group when adjusting for dialysis technique and donor age (Table 3 ; odds ratio, 3.409; 95% confidence interval [95% CI], 1.701, 6.830; P < 0.001) and while additionally adjusting mean mycophenolic acid AUC 0-12 h over time (Table 3 ; odds ratio, 3.658; 95% CI, 1.729, 7.738; P < 0.001). Other factors (e.g. sex, aetiology of chronic kidney disease, peak panel-reactive antibody, second graft, cytomegalovirus infection, cold ischaemia time or induction therapy) were not included in the model as none was associated with treatment failure in bivariate analyses.
Secondary endpoints are shown in Table 4 [17]. The mean eGFR decreased between baseline and 2 years in the usual-exposure group (−4.27 ± 8.06 ml/min/1.73 m 2 ) and increased in the low-exposure group (+0.57 ± 8.80 ml/min/1.73 m 2 ; P < 0.001). For patients who remained on their allocated treatment in the low-exposure group, the reduction in cyclosporine exposure by 50% was quickly followed by an increase in eGFR that was maintained throughout the follow-up (Supplemental Figure) . By contrast, eGFR progressively decreased over time in the usual-exposure group. Mean systolic and diastolic blood pressures were both significantly lower in the low-exposure group (P = 0.03 and P = 0.008, respectively) despite the similarity in the mean number of antihypertensive agents used by each group.
Findings of a sensitivity analysis that assumed maximal bias for the four patients excluded from the intention-totreat analysis confirmed the results of the primary efficacy analysis. Indeed, with the two excluded patients allocated to the usual-exposure arm counted as successes and the two excluded patients allocated to the low-exposure arm counted as failures, treatment failure would have occurred in 37 out of 103 (36%) patients in the usual-exposure group and in 21 out of 108 (19%) patients in the low-exposure group, with this difference remaining significant (P = 0.007).
Renal biopsies
In total, 46 biopsies were performed in 45 patients. An acute rejection episode was confirmed in nine patients, three of whom were in the usual-exposure group (Banff grade Type I in two patients and Type II in one patient) and six in the low-exposure group (Type II in five patients and Type III in one patient). Borderline lesions were found in three patients (two in the usual-exposure and one in the low-exposure groups), and chronic allograft nephropathy was diagnosed in four patients (two in each group). Nephrotoxicity was diagnosed in 17 patients, including 12 in the usual-exposure group (three cases were mild, seven were moderate and two were severe) and five in the low-exposure group (one case was mild and four were severe). Thrombotic microangiopathy was reported in one patient with a posteriori diagnosis of a deficit in factor H. Nephropathy relapsed in three patients. Other biopsies showed miscellaneous changes not considered to be due to rejection or to cyclosporine nephrotoxicity: acute tubular necrosis, lesions transmitted from the donor (interstitial fibrosis, arteriolosclerosis and diabetes mellitus), urinary obstruction and bacterial infection. Neither polyoma virus infection nor post-transplant lymphoproliferative disorder was reported.
Safety
In total, 130 (69 in the usual-exposure group; 61 in the low-exposure group) adverse events were reported in 62 (35 in the usual-exposure group; 27 in the low-exposure group) patients, including 41 bacterial infections (19 in the usual-exposure group; 22 in the low-exposure group; P = 0.30) and 13 viral infections (nine in the usualexposure group; four in the low-exposure group; P = 0.13). Nine incident cases of non-melanomatous skin cancer were reported among six patients, eight in the usual-exposure group among five patients and one in the low-exposure group (P = 0.11). Incident solid carcinoma was reported in four patients, two in each group (P = 1.0). No cases of lymphoma were reported.
Discussion
This trial demonstrated that, with a standardized monitoring schedule and a three-point pharmacokinetic sampling strategy, cyclosporine exposure could be reduced safely by 50% in patients maintained on cyclosporine and mycophenolate mofetil during their second post-transplant year. Even in a population of corticosteroid-free patients at moderate risk of graft dysfunction, our minimization strategy had a positive effect on renal function.
The beneficial effect observed in the cyclosporine lowexposure group is likely due to a diminution in cyclosporine-induced nephrotoxicity as suggested by the initial improvement observed in the eGFR at the time of the reduction in cyclosporine exposure. There was no other valid explanation for this observed improvement. There were no differences between the two groups at baseline in number of mismatches, peak panel-reactive antibody, donor age, duration of cold ischaemia, delayed graft function, hypertension or prior acute rejection at baseline, nor were there differences in the occurrence of new-onset diabetes mellitus, changes in lipid levels and number of antihypertensive (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diuretics) and lipid-lowering drugs used at 24 months. Improvements were accompanied by a non-significant increase in the number of acute rejection episodes but did not lead to an excess of graft losses.
A reduction in cardiovascular risk might also be expected with cyclosporine dose reduction. Cardiovascular complications are frequent among renal allograft recipients [20] ; CNIs contribute to the risk of cardiovascular events by promoting the development of new-onset diabetes mellitus, hypertension and hyperlipidaemia. In the present study, mean systolic and diastolic blood pressures were significantly lower in the low-exposure group. Blood pressure reductions, which have been reported to be associated with a 20% decrease in the risk of cardiovascular adverse events in the general population [21] , may have even greater benefits in renal allograft recipients with a high risk of cardiovascular disease.
Long-term immunosuppression is known to increase the risk of malignancy [22] . Although the period of followup in this study was too short to identify any significant differences between the treatment groups in the incidence of malignancy, it was noted that eight cases of a faster-occurring non-melanomatous skin cancer were observed in the cyclosporine usual-exposure group versus only one in the lowexposure group.
Our study was novel in that cyclosporine dose adjustments were tailored to the cyclosporine AUC 0-12 h obtained using a Bayesian estimator and only three plasma concentrations measured within a 3-h period. The study was not designed to compare the accuracy of cyclosporine AUC 0-12 h with that of the cyclosporine trough levels in predicting dosing, although several arguments favour the use of the cyclosporine AUC 0-12 h . AUC 0-12 h -based dosing is more precise than that based on trough levels as the target trough levels may approach or even be less than the quantification limit of most commercial assays. Thus, using an AUC 0-12 h is safer than using trough levels to support minimization strategies. Although partly based on trough levels, our approach provided greater accuracy than would have resulted from the use of trough levels alone as evidenced by lower comparative intra-patient and inter-patient coefficients of variation. Moreover, recently published cyclosporine minimization studies using trough-based dosing found that many patients did not maintain the low target trough levels, did not have their cyclosporine dose tapered or withdrawn as per the protocol [23] or maintained mean cyclosporine trough levels at the high end of the minimization target range throughout the study [24] . The fact that the CNI minimization arms did not reach the adequate levels was probably due to the fear of low CNI exposure during the critical first year post-transplant period. In these studies, the authors proposed that further reductions in cyclosporine exposure would probably not have provided adequate immunosuppression [24] .
Another option would have been to rely on 2-h postdose cyclosporine concentrations (C2); C2 currently is recommended for cyclosporine monitoring but was not in use when the trial was designed. A good correlation exists between C2 and the AUC measured in the first post-transplantation months [25] , but cyclosporine exposure can be inadequately represented by C2 levels such as in patients with delayed absorption [26] . Moreover, it is unknown whether the high correlation between C2 levels and cyclosporine AUC 0-12 h still exists when cyclosporine doses are markedly reduced long after transplantation and, if so, which C2 targets should be used for cyclosporinesparing strategies. In the absence of additional data, it may be advisable to use a more precise pharmacokinetic technique than C2 measurement when a substantial reduction in cyclosporine exposure is required. Similarly, for tacrolimus, the most frequently used CNI for new kidney transplants, choosing the most effective minimization approach is also difficult. In the Efficacy Limiting Toxicity Elimination-Symphony Study [23] , mean tacrolimus trough levels were consistently at the high end of the minimization target range throughout the study. Thus, for substantial reductions in tacrolimus exposure, such as that achieved with cyclosporine in our study, pharmacokinetic monitoring is likely a necessity. A simplified pharmacokinetic strategy adapted to cyclosporine in our study should be applicable to the reduction of tacrolimus exposure in kidney transplant recipients.
Minimization of cyclosporine exposure also affected mycophenolic acid pharmacokinetics. In all patients, a higher mean mycophenolic acid AUC 0-12 h was associated independently with a decreased risk of treatment failure while a lower minimum mycophenolic acid AUC 0-12 h was significantly associated with an increased risk of acute rejection, which is consistent with previously reported findings [4, 27] . These outcomes suggest that mycophenolic acid monitoring would be useful in avoiding the detrimental effects of lower mycophenolic acid exposure during dose minimization. Several studies have reported a lower exposure to mycophenolic acid in patients receiving mycophenolate mofetil in combination with cyclosporine than in those receiving mycophenolate mofetil and tacrolimus [28, 29] or sirolimus [30] or mycophenolate mofetil alone [31] . Most studies indirectly support the hypothesis that cyclosporine decreases mycophenolic acid enterohepatic cycling through inhibition of mycophenolic acidphenyl glucuronide excretion into the bile. Indeed, in contrast to tacrolimus, cyclosporine is an inhibitor of the multidrug resistance-associated protein 2 involved in the biliary excretion of mycophenolic acid-phenyl glucuronide [32] . However, a 14% increase in exposure to mycophenolate, generally regarded as a second-line immunosuppressant, can only partly offset the overall immunosuppressive reduction brought about by a 50% diminution of the first-line immunosuppressant cyclosporine.
The principal limitation of this study was the lack of protocol-specified systematic biopsies. Although we were aware at the time the study was designed that the lack of systematic biopsies precluded full identification of infra-clinical rejection or nephrotoxicity lesions, it was in accordance with standard practice. The low incidence of chronic allograft nephropathy also could have reflected, at least in part, the lack of systematic biopsies. Although kidney function is a surrogate marker of graft survival [33] , this relationship does not elucidate whether our strategy facilitated an increase in graft survival. Long-term follow-up would have been necessary. Another drawback of the study design was the lack of pharmacoeconomic analysis. While our three-point sampling strategy enabled us to ensure cyclosporine minimization in a population of corticosteroid-free patients at moderate risk of dysfunction, the potential benefits will need to be weighed against the burden of drawing levels over a 3-h period, especially in the setting of a busy outpatient transplant unit.
Conclusion
In conclusion, this study has demonstrated that, in renal allograft recipients with stable renal function receiving mycophenolate mofetil maintenance therapy in the absence of corticosteroids, a 50% reduction of cyclosporine exposure was safe and was associated with a decrease in the risk of graft dysfunction. This reduction in cyclosporine dosage can be guided by a standardized monitoring schedule to reliably reduce and maintain exposure. A similar approach should also be effective in controlling exposure to mycophenolic acid. From our results, we recommend performance of cyclosporine and mycophenolic acid pharmacokinetic monitoring with only four plasma samples. More work is needed, however, to determine the optimal target of mycophenolic acid exposure in the framework of cyclosporine minimization strategies and to study whether cyclosporine trough levels give the same results. From our findings, we believe that, in the absence of immunological monitoring, immunosuppressive drug minimization can be achieved through a standardized approach to pharmacokinetic monitoring and concentration control.
